Global Etilefrine Hydrochloride Drug Market Size, Share and Trends Analysis Report, By Disease (Hypotension and Others), By End User (Hospital, Clinic, and Others), Forecast (2022-2028)

The etilefrine hydrochloride drug market is anticipated to grow at a significant CAGR 3% during the forecast period (2022-2028). Etilefrine hydrochloride Drug is prescribed for the treatment of hypotension. Etilefrine is a type of cardiac stimulant that increases blood pressure. This increases the intensity of cardiac output and helps in the stimulation of alpha and beta receptors. Research and trials done for this drug indicate that it has a much higher affinity for beta 1 as compared to beta 2 receptors. This drug consistently increases the pulse rate in the human body. Etilefrine hydrochloride tends to rise the stroke volume and mean arterial pressure in an individual who has the problem of hypotension. In some cases when there is a fall in pulse rate as well as cardiac output, propranolol is given by intravenous method which is followed by a dose of etilefrine. As per the French Health Product Agency,  etilefrine has an unfavorable harm-benefit balance. The the increasing demand for etilefrine hydrochloride in the pharmaceutical industry and laboratory use is the major factors driving the market gorwth. The global etilefrine hydrochloride drug market is segmented by disease and by end-user. Based on disease, the market is sub-segmented into hypotension and others. Based on end-user, the market is sub-segmented into hospitals, clinics, and others. Low blood pressure or hypotension is a condition that in many cases does not pose any harmful effects. Many people experience dizziness and fainting in low blood pressure and it can be life-threatening. As per health experts, a systolic reading of lower than 90 millimeters of mercury and a diastolic reading of 60 millimeters of mercury is considered a case of hypotension. Fainting, blurry vision nausea, and fatigue are some common symptoms of hypotension.

The global etilefrine hydrochloride drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The Asia-Pacific is expected to drive the market during the forecast period. A major reason for this is that the Asia Pacific region has the highest percentage of geriatric population that is suffering from low blood pressure or hypotension, due to which the demand for hydrochloride drug is high in the region. As per an article published in the Journal Age And Aging, around 35.2% of the geriatric population is affected by orthostatic hypotension.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Shenzhen Oriental Pharmaceutical Co., Ltd, Boehringer Ingelheim International GmbH., FUJIFILM Wako Pure Chemical Corp.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Etilefrine Hydrochloride Drug Market Report By Segment

By Disease

• Hypotension
• Others

By End-User

• Hospital
• Clinic
• Others